Liquidia reports Q2 EPS (49c), consensus (39c)

Reports Q2 revenue $8.84M, consensus $3.89M. Cash and cash equivalents totaled $173.4M as of June 30, vs. $176.5M as of December 31, 2024. CEO Roger Jeffs said: “Q2 was a defining period for Liquidia (LQDA) with the FDA approval and rapid commercial launch of Yutrepia – treprostinil – inhalation powder…In the 11 weeks since approval, we’ve recorded over 900 unique patient prescriptions leading to more than 550 patient starts. This initial demand has exceeded my own high expectations. The robust and increasing uptake reflects a clear need for more flexible and better-tolerated prostacyclin therapies. We’ve already seen broad demand across both indications from both cardiologists and pulmonologists. Notably, this early momentum has been achieved ahead of full payor adoption, highlighting the potential for accelerating growth as we continue to expand market access during the third and fourth quarters… With this strong early commercial execution, compelling clinical evidence, and financial flexibility through our recent funding under our financing agreement with Healthcare Royalty, we are well positioned to scale access to Yutrepia , expand our clinical programs, and deliver durable value for patients and shareholders.”